Riverwater Partners’ Small Cap Strategy Q3 2025 investor letter reported solid results but lagged the benchmark due to the market’s preference for lower-quality companies. The strategy focuses on higher-quality companies with enduring fundamentals. Haemonetics Corporation (HAE) was highlighted in the letter, with a 8.06% one-month return and $80.40 closing share price on December 15, 2025.

Riverwater Partners Small Cap Strategy discussed Haemonetics Corporation (HAE) in its Q3 2025 investor letter, noting challenges in certain product lines but expressing belief in the company’s essential role in hospital blood management. The position was exited during the quarter to redeploy capital into opportunities with clearer near-term catalysts.

Haemonetics Corporation (HAE) is not among the 30 Most Popular Stocks Among Hedge Funds. Despite reporting a 5% revenue decline in Q2 2026, the company’s potential as an investment is acknowledged. However, certain AI stocks are seen as offering greater upside potential with less downside risk. Investors seeking an undervalued AI stock can explore the free report on the best short-term AI stock.

Read more at Yahoo Finance: Riverwater Partners Small Cap Strategy Sold Its Stake in Haemonetics Corporation (HAE) in Q3